News
Fight to derail Mark Green intensifies as House Dems urge opposition
31 House Democrats urge Senate to reject nomination over anti-trans views
LGBT advocates are trying to derail the nomination of Tenn. state Sen. Mark Green as Army secretary. (Photo courtesy of Dr. Mark Green for Tennessee)
The effort to derail the appointment of Mark Green as Army secretary intensified this week as the nominee lashed out over LGBT rights supporters campaign against him and House Democrats urged the Senate to reject his confirmation.
In a letter dated April 24, 31 House Democrats call on the leaders of the Senate Armed Services Committee to oppose Green on the basis that the anti-LGBT positions he’s taken over his political career have “made it clear that he cannot be trusted to ensure that LGBT soldiers are able to serve their country without discrimination or harassment.”
“LGBT soldiers are willing to make tremendous sacrifices to protect our rights and freedoms,” the letter says. “It would be deeply disrespectful to their service to appoint a secretary of the Army whose history of homophobia and transphobia makes it clear that he is not willing to do the same for them.”
Spearheading the letter was Rep. Joe Kennedy III (D-Mass.), who said in an interview with the Washington Blade he hasn’t yet had conversations with senators about the nomination, but thinks the letter makes the clear the opposition of signers to the nominee.
Kennedy, the chair of the Congressional Transgender Task Force, pointed out as Army secretary Green would be in charge of as many as 11,000 transgender people serve the U.S. military, according to a RAND Corp. estimate.
“Given what he said, what he has made clear his beliefs are, he has no business being overseeing the Army or any other branch of the armed services, or the United States writ large,” Kennedy said.
Nominated by President Trump earlier this month, Green spearheaded legislation as a Tennessee state legislator that would have barred municipalities from enacting pro-LGBT non-discrimination ordinances and another bill seeking to bar transgender students from using the restroom consistent with their gender identity. Green also supported a law signed by Gov. Bill Haslam allowing mental health practitioners to reject LGBT patients for religious reasons.
But it’s Green’s remarks on LGBT people that have particularly raised eyebrows. During a town hall event in Tennessee before the Chattanooga Tea Party last year, Green equated being transgender to having a “disease,” a view major medical organizations have rejected.
The LGBT media watchdog GLAAD also uncovered audio of an interview of Green last year on an online radio show in which he said he wants to “crush evil” by keeping transgender women from the restroom, comparing them to ISIS.
“So that means as a state senator, my responsibility very clearly in Romans 13 is to create an environment where people who do right are rewarded and the people who do wrong are crushed,” Green said. “Evil is crushed. So I’m going to protect women in their bathrooms, and I’m going to protect our state against potential infiltration from the Syrian ISIS people in the refugee program. And whoever wants to stand up and take me on that, I’m ready to fight.”
Defending himself in a Facebook post, Green accused the “liberal left” of splicing his words and “blatantly falsifying what I’ve said,” denying that he ever called transgender people evil. (The quote from the radio interview is accurate.) The Facebook post links to an article on anti-LGBT website, ChristianFighterPilot.com, which asserts “homosexual activists” are target Green because he’s a Christian.
Asked whether he thinks Green’s nomination will ultimately be derailed, Kennedy said he’d urge senators to take a close look at Green and “ask a pretty simple question as to whether they believe somebody who has described a significant portion of the American population as ‘evil’ should be in charge of our Army.”
“This gets back to just a fundamental principle of whether our government is going to recognize, see and celebrate diversity and inclusion and be able to acknowledge and lift up those who are willing to put their life on the line to defend the rest of us,” Kennedy said.
The Blade has sought comment on the letter from House Democrats from the offices of Sens. John McCain (R-Ariz.), chair of the Senate Armed Services Committee, and Jack Reed (D-R.I.), top Democrat on the committee.
Although the Trump administration has made other anti-LGBT appointments, such as Jeff Sessions as U.S. attorney general, Kennedy said the nomination of Mark Green as Army secretary is “beyond the pale” compared to the other actions.
“I think we’ve seen a pattern of actions by this administration that have targeted the LGBT community,” Kennedy said. “All of them, I believe, have been horrible. This one, I think, the idea that somebody who holds these beliefs about the trans community, you elevate that believes such view to the secretary of the Army, I think is just beyond the pale.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Rehoboth Beach
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
$4.5 million listing includes real estate; business sold separately
Gay gasps could be heard around the DMV earlier this week when a real estate listing for Rehoboth Beach’s iconic Blue Moon bar and restaurant hit social media.
Take a breath. The Moon is for sale but the longtime owners are not in a hurry and are committed to preserving its legacy as a gay-friendly space.
“We had no idea the interest this would create,” Tim Ragan, one of the owners, told the Blade this week. “I guess I was a little naive about that.”
Ragan explained that he and longtime partner Randy Haney are separating the real estate from the business. The two buildings associated with the sale are listed by Carrie Lingo at 35 Baltimore Ave., and include an apartment, the front restaurant (6,600 square feet with three floors and a basement), and a secondary building (roughly 1,800 square feet on two floors). They are listed for $4.5 million.
The bar and restaurant business is being sold separately; the price has not been publicly disclosed.
But Ragan, who has owned the Moon for 20 years, told the Blade nothing is imminent and that the Moon remains open through the holidays and is scheduled to reopen for the 2026 season on Feb. 10. He has already scheduled some 2026 entertainment.
“It’s time to look for the next people who can continue the history of the Moon and cultivate the next chapter,” Ragan said, noting that he turns 70 next year. “We’re not panicked; we separated the building from the business. Some buyers can’t afford both.”
He said there have been many inquiries and they’ve considered some offers but nothing is firm yet.
Given the Moon’s pioneering role in queering Rehoboth Beach since its debut 44 years ago in 1981, many LGBTQ visitors and residents are concerned about losing such an iconic queer space to redevelopment or chain ownership.
“That’s the No. 1 consideration,” Ragan said, “preserving a commitment to the gay community and honoring its history. The legacy needs to continue.” He added that they are not inclined to sell to one of the local restaurant chains.
You can view the real estate listing here.
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
